1. Characteristics

2. How does NAD+ work?

At its core, NAD+ operates as a central redox coenzyme, shuttling electrons through key metabolic pathways including glycolysis, fatty acid oxidation, and the citric acid cycle. It also serves as an essential co-substrate for sirtuins, NAD+-dependent deacetylases responsible for removing acetyl groups from proteins and regulating gene expression.

Sirtuin activity connects NAD+ to DNA repair, cellular stress responses, inflammation, and metabolic homeostasis, accounting for much of the compound's presence in scientific literature. NAD+ is further consumed by poly(ADP-ribose) polymerases (PARPs) during the DNA damage response; while PARPs are integral to repair, excessive activation depletes cellular NAD+ reserves. CD38, which produces cyclic ADP-ribose, represents another significant consumer of NAD+.

Cells replenish NAD+ either through de novo synthesis from tryptophan or via salvage pathways utilizing precursors such as nicotinic acid, nicotinamide, and nicotinamide riboside, the latter being a principal strategy in experimental research aimed at elevating intracellular NAD+ concentrations.

3. NAD+ Benefits

Preclinical and experimental findings suggest that sustaining NAD+ status may produce the effects outlined below. All observations derive from research models and should not be interpreted as medical claims.

• Longevity: Lifespan extension has been reported in yeast, worm, and mouse models where NAD+ pathways were supported, with NAD+-dependent sirtuins identified as a key signaling family underlying these outcomes.
• Metabolic health:Central to cellular energy metabolism, NAD+ elevation in model systems has been associated with improved mitochondrial function, glucose handling, and insulin sensitivity, with potential relevance to obesity, type 2 diabetes, and metabolic syndrome.
• Cardiovascular health: Research involving NAD+ precursors has documented cardiovascular effects including favorable shifts in blood pressure markers, reduced inflammatory signaling, and protection against oxidative stress.
• Neurological health: Given NAD+'s role in neuronal function and cerebral energy metabolism, elevating its levels in experimental models has been investigated as a strategy to support resilience against age-related cognitive decline and neurodegenerative processes.
• DNA repair: As a substrate for PARPs, adequate NAD+ availability supports PARP activity and broader DNA repair mechanisms, contributing to genomic stability.
• Inflammation: Sirtuin activation has been associated with anti-inflammatory effects across multiple models, with NAD+ support serving as a research tool for studying modulation of chronic inflammatory pathways.

4. Side effects

Clinical and supplemental studies generally find NAD+ precursors such as nicotinic acid, nicotinamide, and nicotinamide riboside to be well-tolerated. However, higher doses of nicotinic acid are known to cause flushing, itching, and gastrointestinal upset, while high doses of nicotinamide have been associated with gastrointestinal complaints and potential liver toxicity.

All use of this material must remain strictly within a laboratory research context and must not involve self-use as a drug, supplement, or medical treatment. Any dosing information from clinical or supplemental contexts is referenced only to inform research design—not for self-administration.

5. Summary

NAD+ is a central coenzyme that participates in energy metabolism, DNA repair, cell signaling, and the cellular stress response. Experimentally, NAD+ status can be influenced either by providing NAD+ itself or by supplying precursors that cells convert into NAD+ through salvage pathways.

Across multiple model systems, maintaining NAD+ has been linked to favorable findings in areas such as longevity, metabolic health, cardiovascular and neurological function, DNA repair, and regulation of inflammation. Even though NAD+ precursors are generally regarded as safe in clinical research, any use of these materials should be overseen by qualified professionals and remain fully compliant with applicable regulations and ethical standards.

6. References

• Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529–547. doi: 10.1016/j.cmet.2018.02.011. PubMed Central
• Fang EF, Lautrup S, Hou Y, Demarest TG, Croteau DL, Mattson MP, Bohr VA. NAD+ in Aging: Molecular Mechanisms and Translational Implications. Trends Mol Med. 2017;23(10): 899–916. doi: 10.1016/j.molmed.2017.08.001. PubMed Central
• Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4): 528–536. doi: 10.1016/j.cmet.2011.08.014. PubMed Central
• Trammell SA, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. doi: 10.1038/ncomms12948. PubMed

7. Research use